Forget Pills! Could This Device Put an End to Obesity in America?
We've witnessed three oral anti-obesity meds approved since mid-2012, but this newly approved device could be a game-changer.
Why VIVUS, Inc. Stock Descended 14% in December
Instead of shrinking waistlines, VIVUS shareholders saw their shares shrink in value by 14% in December. Find out what troubled VIVUS in December and whether or not this dip represents a buying opportunity.
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
Afrezza could be a game-changing inhaled diabetes therapy, but it must overcome an obstacle that crushed previous potential game changers.
Arena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?
Investors bid up Arena Pharmaceuticals 76% after the biotech releases positive phase 1 data for APD334.
Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December
Arena Pharmaceuticals stock took a tumble in December after a rival receives good news in the EU. Find out whether this dip is a buying opportunity or a red flag to keep your distance.